301569 N联亚药业
2026/06 - 中期2025/122024/122023/12

盈利能力分析
净资产收益率 ROE (%)6.73111.98715.68615.177--
总资产报酬率 ROA (%)5.97210.48313.67713.220--
投入资产回报率 ROIC (%)6.35511.31014.72914.118--

边际利润分析
销售毛利率 (%)61.80955.72854.48650.189--
营业利润率 (%)33.38029.35133.55119.617--
息税前利润/营业总收入 (%)36.51527.87328.29614.671--
净利润/营业总收入 (%)28.67425.44130.03216.531--

收益指标分析
经营活动净收益/利润总额(%)102.374106.069102.923103.492--
价值变动净收益/利润总额(%)0.3120.9511.1673.076--
营业外收支净额/利润总额(%)0.1140.114-0.187-0.934--

偿债能力分析
流动比率 (X)13.1139.7148.63710.944--
速动比率 (X)11.4718.4267.2378.603--
资产负债率 (%)10.22712.37512.73312.896--
带息债务/全部投入资本 (%)0.3010.4330.1240.033--
股东权益/带息债务 (%)31,473.86321,702.68076,098.856279,254.112--
股东权益/负债合计 (%)877.793708.104685.342675.444--
利息保障倍数 (X)11.790-18.438-5.450-3.079--

营运能力分析
应收账款周转天数 (天)63.02861.32450.92258.076--
存货周转天数 (天)208.036200.917223.717270.388--